Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies
AssigneeUniversite Libre de Bruxelles
InventorsOberdan Leo, Mara Galli, Frédéric Van Gool
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of sirtuin inhibitors for reducing TNF-alpha production by cells and organisms. The invention also concerns prophylactic and therapeutic applications of sirtuin inhibitors in TNF-alpha mediated pathologies, such as various inflammatory and autoimmune disorders.
Claims13
A method for reducing the production of TNF-alpha in cells in vitro, comprising exposing said cells to an inhibitor of one or more sirtuins other than suramin.
A method for reducing the production of TNF-alpha in cells in vitro, comprising exposing said cells to a cell-permeable inhibitor of one or more sirtuins.
An inhibitor of one or more sirtuins other than suramin for (a) reducing the production of TNF-alpha in a subject and/or (b) reducing local or systemic inflammation in a subject and/or (c) treating a TNF-alpha mediated pathology in a subject having local or systemic excessive or deregulated production of TNF-alpha.
A cell-permeable inhibitor of one or more sirtuins for (a) reducing the production of TNF-alpha in a subject and/or (b) reducing local or systemic inflammation in a subject and/or (c) treating a TNF-alpha mediated pathology in a subject having local or systemic excessive or deregulated production of TNF-alpha.
Dependencies are inferred from the claim text.